baricitinib vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly and partners
NCT03334396 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.
Next expected readout: May 2030 · NCT07262983 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% (met)
Result source: NCT03334422
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: November 2026 · NCT06389136 (registry estimate)
Reported efficacy
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)
Result source: NCT03607422
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | baricitinib | upadacitinib |
|---|---|---|
| EASI-75 | 31.5% vs 17.2%+14.3 vs placeboNCT0342810065 other results
| 60.1% vs 13.3%+46.8 vs placeboNCT0360742263 other results
|
| IGA 0/1 with 2-point improvement | 13% vs 12.9%+0.1 vs placeboNCT034281005 other results
| —Trial running · NCT03568318 |
| EASI-90 | 16% vs 4.8%+11.2 vs placeboNCT0333439615 other results
| 42.4% vs 5.4%+37 vs placeboNCT0360742214 other results
|
| EASI, % change | -59.4% vs -34.8%−24.5 vs placeboNCT0333439612 other results
| -74.1% vs -34.5%−39.6 vs placeboNCT0360742269 other results
|
EASI-75
- baricitinib
- 31.5% vs 17.2%+14.3 vs placeboNCT03428100
65 other results
- 27.6% vs 17.2% NCT03428100
- 29.5% vs 8.2% NCT03435081
- 51.4% vs 38.5% NCT03334435
- 42.9% vs 38.2% NCT03334435
- 37% vs 26.9% NCT03428100
- 51.4% vs 44.2% NCT03334435
- 44.4% vs 47.1% NCT03334435
- 79.8% vs 44.6% NCT03334435
- 93% vs 63.3% NCT03334435
- 25% vs 17.2% NCT03428100
- 24.8% vs 8.8% NCT03334396
- 21.1% vs 6.1% NCT03334422
- 47.7% vs 22.9% NCT03733301
- 39.8% vs 54.3% NCT03334435
- 30.3% vs 26.9% NCT03428100
- 27.6% vs 17.2% NCT03428100
- 40.9% vs 54.3% NCT03334435
- 12.9% vs 8.2% NCT03435081
- 61.5% vs 71.4% NCT03334435
- 64.3% vs 42.3% NCT03334435
- 55.6% vs 55.9% NCT03334435
- 73.8% vs 43.5% NCT03334435
- 76.7% vs 55.1% NCT03334435
- 64.8% vs 38.5% NCT03334435
- 52.8% vs 38.2% NCT03334435
- 74.1% vs 44.2% NCT03334435
- 47.2% vs 47.1% NCT03334435
- 58.3% vs 44.6% NCT03334435
- 73.9% vs 44.6% NCT03334435
- 76.7% vs 63.3% NCT03334435
- 83.3% vs 63.3% NCT03334435
- 53.2% vs 71.4% NCT03334435
- 55.1% vs 71.4% NCT03334435
- 18.7% vs 8.8% NCT03334396
- 17.9% vs 6.1% NCT03334422
- 70.4% vs 42.3% NCT03334435
- 67.9% vs 55.9% NCT03334435
- 43.1% vs 22.9% NCT03733301
- 58.3% vs 43.5% NCT03334435
- 72.8% vs 43.5% NCT03334435
- 63.6% vs 62.1% NCT03428100
- 74.4% vs 55.1% NCT03334435
- 83.3% vs 55.1% NCT03334435
- 51.1% vs 38.5% NCT03334435
- 33.3% vs 26.9% NCT03428100
- 46.7% vs 44.2% NCT03334435
- 69.2% vs 44.6% NCT03334435
- 68.2% vs 72.4% NCT03428100
- 89.6% vs 63.3% NCT03334435
- 44.4% vs 71.4% NCT03334435
- 17.3% vs 8.8% NCT03334396
- 12.8% vs 6.1% NCT03334422
- 62.2% vs 42.3% NCT03334435
- 58.2% vs 43.5% NCT03334435
- 32.2% vs 32% NCT03952559
- 40% vs 32% NCT03952559
- 52.5% vs 32% NCT03952559
- 76.5% vs 62.1% NCT03428100
- 30.1% vs 17.2% NCT03428100
- 22.6% vs 17.2% NCT03428100
- 79.2% vs 55.1% NCT03334435
- 65.6% vs 54.3% NCT03334435
- 70.6% vs 72.4% NCT03428100
- 57.1% vs 62.1% NCT03428100
- 85.7% vs 72.4% NCT03428100
- upadacitinib
- 60.1% vs 13.3%+46.8 vs placeboNCT03607422
63 other results
- 69.6% vs 16.3% NCT03569293
- 72.9% vs 13.3% NCT03607422
- 79.7% vs 16.3% NCT03569293
- 72.4% vs 62.6% NCT03738397
- 33% vs 3.6% NCT03607422
- 38.1% vs 3.6% NCT03569293
- 44% vs 3.6% NCT03607422
- 47.4% vs 3.6% NCT03569293
- 69% vs 13.3% NCT03607422
- 74.6% vs 12.1% NCT03569293
- 37.9% vs 6.7% NCT03607422
- 39.7% vs 3.4% NCT03569293
- 73.4% vs 13.3% NCT03607422
- 84.5% vs 12.1% NCT03569293
- 53.2% vs 6.7% NCT03607422
- 55.8% vs 3.4% NCT03569293
- 44.3% vs 18.2% NCT03738397
- 52.4% vs 9.8% NCT02925117
- 52.4% vs 7.3% NCT02925117
- 69% vs 9.8% NCT02925117
- 81% vs 7.3% NCT02925117
- 28.6% vs 9.8% NCT02925117
- 31% vs 7.3% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 80% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 85.7% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 20% vs 11.1% NCT02925117
- 25% vs 11.1% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 9.1% vs 11.1% NCT02925117
IGA 0/1 with 2-point improvement
- baricitinib
- 13% vs 12.9%+0.1 vs placeboNCT03428100
5 other results
- 21.7% vs 9.7% NCT03428100
- 18.9% vs 12.9% NCT03428100
- 15.1% vs 9.7% NCT03428100
- 20.4% vs 12.9% NCT03428100
- 12.9% vs 9.7% NCT03428100
- upadacitinib
- —Trial running · NCT03568318
EASI-90
- baricitinib
- 16% vs 4.8%+11.2 vs placeboNCT03334396
15 other results
- 13% vs 2.5% NCT03334422
- 14.1% vs 6.5% NCT03428100
- 24.3% vs 13.8% NCT03733301
- 10.6% vs 4.8% NCT03334396
- 8.9% vs 2.5% NCT03334422
- 10.3% vs 6.5% NCT03428100
- 20.5% vs 3.4% NCT03435081
- 16.5% vs 13.8% NCT03733301
- 8.7% vs 4.8% NCT03334396
- 6.4% vs 2.5% NCT03334422
- 8.6% vs 6.5% NCT03428100
- 7.5% vs 3.4% NCT03435081
- 11.6% vs 12.3% NCT03952559
- 21.7% vs 12.3% NCT03952559
- 30% vs 12.3% NCT03952559
- upadacitinib
- 42.4% vs 5.4%+37 vs placeboNCT03607422
14 other results
- 53.1% vs 8.1% NCT03569293
- 58.5% vs 5.4% NCT03607422
- 65.8% vs 8.1% NCT03569293
- 48.3% vs 1.7% NCT03607422
- 47.6% vs 3.4% NCT03569293
- 62% vs 1.7% NCT03607422
- 74.1% vs 3.4% NCT03569293
- 61.6% vs 40.3% NCT03738397
- 26.2% vs 2.4% NCT02925117
- 26.2% vs 0% NCT02925117
- 50% vs 2.4% NCT02925117
- 45.2% vs 0% NCT02925117
- 14.3% vs 2.4% NCT02925117
- 9.5% vs 0% NCT02925117
EASI, % change
- baricitinib
- -59.4% vs -34.8%−24.5 vs placeboNCT03334396
12 other results
- -54.9% vs -28.9% NCT03334422
- -63.3% vs -42.7% NCT03428100
- -67.2% vs -45.1% NCT03733301
- -51.9% vs -34.8% NCT03334396
- -56.0% vs -42.7% NCT03428100
- -54.8% vs -28.9% NCT03334422
- -54.4% vs -34.1% NCT03435081
- -58.2% vs -45.1% NCT03733301
- -48.2% vs -34.8% NCT03334396
- -41.7% vs -28.9% NCT03334422
- -60.3% vs -42.7% NCT03428100
- -46.7% vs -34.1% NCT03435081
- upadacitinib
- -74.1% vs -34.5%−39.6 vs placeboNCT03607422
69 other results
- -80.2% vs -40.7% NCT03569293
- -84.7% vs -34.5% NCT03607422
- -87.7% vs -40.7% NCT03569293
- -77.8% vs -42.2% NCT03607422
- -82.1% vs -43.5% NCT03569293
- -84.8% vs -42.2% NCT03607422
- -89.4% vs -43.5% NCT03569293
- -61.7% vs -23% NCT02925117
- -74.4% vs -23% NCT02925117
- -39.4% vs -23% NCT02925117
- 582.3% vs 50.7% NCT02925117
- 65.7% vs 50.7% NCT02925117
- -65.4% vs -17.5% NCT02925117
- 607.3% vs 13.5% NCT02925117
- 72.6% vs 13.5% NCT02925117
- 613.3% vs -2.3% NCT02925117
- 151.7% vs -2.3% NCT02925117
- 608.8% vs -31.2% NCT02925117
- 154.1% vs -31.2% NCT02925117
- 613.8% vs -29.8% NCT02925117
- 104.1% vs -29.8% NCT02925117
- 614.6% vs -35.8% NCT02925117
- 104.1% vs -35.8% NCT02925117
- 614% vs -37.3% NCT02925117
- 130.2% vs -37.3% NCT02925117
- 617.5% vs -37.7% NCT02925117
- 99.3% vs -37.7% NCT02925117
- -73.8% vs 50.7% NCT02925117
- -82.8% vs -17.5% NCT02925117
- -67.5% vs 13.5% NCT02925117
- 898.5% vs 13.5% NCT02925117
- -69.6% vs 13.5% NCT02925117
- -83.1% vs -2.3% NCT02925117
- 771.5% vs -2.3% NCT02925117
- -28.8% vs -2.3% NCT02925117
- -92% vs -31.2% NCT02925117
- 778.9% vs -31.2% NCT02925117
- 140.6% vs -31.2% NCT02925117
- -90.1% vs -29.8% NCT02925117
- 799.5% vs -29.8% NCT02925117
- -13.3% vs -29.8% NCT02925117
- -91.4% vs -35.8% NCT02925117
- 802.1% vs -35.8% NCT02925117
- 63.6% vs -35.8% NCT02925117
- -90.3% vs -37.3% NCT02925117
- 787.8% vs -37.3% NCT02925117
- 24.4% vs -37.3% NCT02925117
- -84.6% vs -37.7% NCT02925117
- 769.7% vs -37.7% NCT02925117
- 39% vs -37.7% NCT02925117
- 186% vs 50.7% NCT02925117
- 79.1% vs 50.7% NCT02925117
- -43.7% vs -17.5% NCT02925117
- 11.8% vs 50.7% NCT02925117
- 791.5% vs 50.7% NCT02925117
- 189.6% vs 13.5% NCT02925117
- 59% vs 13.5% NCT02925117
- 181.5% vs -2.3% NCT02925117
- 63.5% vs -2.3% NCT02925117
- 200.9% vs -31.2% NCT02925117
- 77.6% vs -31.2% NCT02925117
- 189.1% vs -29.8% NCT02925117
- 74.4% vs -29.8% NCT02925117
- 179.9% vs -35.8% NCT02925117
- 71.8% vs -35.8% NCT02925117
- 201.4% vs -37.3% NCT02925117
- 77.7% vs -37.3% NCT02925117
- 170.7% vs -37.7% NCT02925117
- 69.1% vs -37.7% NCT02925117
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety
Coverage. baricitinib: 10 of 10 rows · upadacitinib: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | baricitinib Rows use multiple source trials | upadacitinib Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points | -25.66% (n=115) vs -20.31% (n=105) placebo @ 16wkHigh Dosea,b,c,d NCT03952559 · Phase 3 · registry result, not featured evidence show 2 more doses-21.83% (n=109) vs -20.31% (n=105) placebo @ 16wkLow Dose NCT03952559 · Phase 3 · registry result, not featured evidence -22.06% (n=113) vs -20.31% (n=105) placebo @ 16wkMedium Dose NCT03952559 · Phase 3 · registry result, not featured evidence | -27.1% (n=42) vs -4.1% (n=39) placebo @ 16wk15 mga,b,c,d NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses-30.7% (n=42) vs -4.1% (n=39) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence -11.7% (n=42) vs -4.1% (n=39) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| EASI-50 responder rate · % of participants | 41.6% (n=125) vs 15.3% (n=249) placebo @ 16wk4 mga,b,c,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses30.1% (n=123) vs 15.3% (n=249) placebo @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 26% (n=127) vs 15.3% (n=249) placebo @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 71.4% (n=42) vs 22% (n=41) placebo @ 16wk15 mga,b,c,d NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses83.3% (n=42) vs 22% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 50% (n=42) vs 22% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| EASI-75 responder rate · % of participants No placebo or comparator arm | 45.4% (n=194) @ 24wk4 mga,e,c,d NCT03334435 · Phase 3 · registry result, not featured evidence show 3 more doses32.1% (n=28) @ 24wk4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 45% (n=180) @ 24wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 32.4% (n=34) @ 24wk2 mg NCT03334435 · Phase 3 · registry result, not featured evidence | 97.2% (n=71) @ 24wk15 mga,e,c,d NCT05507580 · Phase 4 · registry result, not featured evidence show 3 more doses69.2% (n=133) @ 24wk15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 88.5% (n=130) @ 24wk30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 52.4% (n=82) @ 24wk30 mg NCT05507580 · Phase 4 · registry result, not featured evidence |
| IGA 0/1 responder rate · % of participants | 13.8% (n=123) vs 4.5% (n=244) placebo @ 16wk4 mga,b,c,d NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses10.6% (n=123) vs 4.5% (n=244) placebo @ 16wk2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.8% (n=125) vs 4.5% (n=244) placebo @ 16wk1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 31% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mga,b,c,d NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses50% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 14.3% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| SCORAD75 responder rate · % of participants | 10.4% (n=125) vs 1.2% (n=249) placebo @ 16wk4 mga,b,c,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses7.3% (n=123) vs 1.2% (n=249) placebo @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 5.5% (n=127) vs 1.2% (n=249) placebo @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 21.4% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mga,b,c,d NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses40.5% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| SCORAD90 responder rate · % of participants | 2.4% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mga,b,c,d NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 2 more doses2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 | 9.5% (n=42) vs 0% (n=41) placebo @ 16wk15 mga,b,c,d NCT02925117 · Phase 2 · registry result, not featured evidence show 2 more doses23.8% (n=42) vs 0% (n=41) placebo @ 16wk30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4% (n=42) vs 0% (n=41) placebo @ 16wk7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 4%4 mgf NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results—4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.1%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.7%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4.9%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.1%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 98%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 97.7%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 7.6%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 6.5%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 14%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 13%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 3.6%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 8.3%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence —4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 32.4%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence | —15 mgg NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 5.2%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 4.1%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 3.2%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 4.5%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 3.3%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 4.9%30 mg QD NCT03569293 · Phase 3 5.2%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 2.6%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 10.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 16.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 8.8%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 11.9%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 26.2%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%4 mgf NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results—4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.6%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.6%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence —High Dose NCT03952559 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 3.1%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.7%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence —1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.1%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 1.6%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 0%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 1.4%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence —1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 2.7%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 0.9%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence —4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 8.1%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence | —15 mgg NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0.4%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 0.4%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 1.6%30 mg QD NCT03569293 · Phase 3 —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 2%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.6%4 mgf NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 50 more results0%4 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%2 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1 mg NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%4 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%2 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 7.3%1 mg NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%High Dose NCT03952559 · Phase 3 · registry result, not featured evidence 1.7%Low Dose NCT03952559 · Phase 3 · registry result, not featured evidence —Medium Dose NCT03952559 · Phase 3 · registry result, not featured evidence 0.8%Mid Dose NCT03952559 · Phase 3 · registry result, not featured evidence 0%High Dose NCT03952559 · Phase 3 · registry result, not featured evidence 9.5%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 13.1%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 5.4%4 mg NCT03334435 · Phase 3 · registry result, not featured evidence 6.4%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 3.3%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.2%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 4.2%2 mg NCT03334435 · Phase 3 · registry result, not featured evidence 9.4%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 1.1%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 2.2%1 mg NCT03334435 · Phase 3 · registry result, not featured evidence 10.9%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16.7%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 28.6%4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16.7%Placebo to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 18.8%4 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 18.8%4 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 4.9%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 4.5%2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 11.1%2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 19.2%2 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence 9.1%Placebo to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 16%2 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 12.5%2 mg to 1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 7.5%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 2.9%1 mg NCT03428100 · Phase 3 · registry result, not featured evidence 15.4%1 mg to 2 mg NCT03428100 · Phase 3 · registry result, not featured evidence 21.4%1 mg to 4 mg NCT03428100 · Phase 3 · registry result, not featured evidence —2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 1.4%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0%2 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0.7%1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 0%1 mg NCT03435081 · Phase 3 · registry result, not featured evidence 3.6%4 mg NCT03733301 · Phase 3 · registry result, not featured evidence 1.8%2 mg NCT03733301 · Phase 3 · registry result, not featured evidence 2.6%4 mg NCT02576938 · Phase 2 · registry result, not featured evidence 5.4%2 mg NCT02576938 · Phase 2 · registry result, not featured evidence | 15.4%15 mgg NCT03607422 · Phase 3 show 48 more results10.9%15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 10.6%15 mg NCT03607422 · Phase 3 16.6%15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 13.8%30 mg NCT03607422 · Phase 3 16.9%30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 17.3%30 mg NCT03607422 · Phase 3 17.4%30 mg NCT03607422 · Phase 3 2.8%30 mg QD NCT03607422 · Phase 3 3.3%15 mg NCT03569293 · Phase 3 12.5%15 mg QD NCT03569293 · Phase 3 3.1%15 mg QD NCT03569293 · Phase 3 14.7%15 mg NCT03569293 · Phase 3 14.3%15 mg NCT03569293 · Phase 3 2.1%15 mg QD NCT03569293 · Phase 3 22.2%30 mg NCT03569293 · Phase 3 10.9%30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 20%30 mg NCT03569293 · Phase 3 18.4%30 mg NCT03569293 · Phase 3 3.3%30 mg QD NCT03569293 · Phase 3 3.5%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.4%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.7%15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.8%30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 5.9%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 5.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.1%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 6.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 0%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 4 mgf nasopharyngitis 9.6% (placebo 10.4%) headache 8% (placebo 6.4%) cough 3.2% (placebo 0.8%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 47 more results4 mg abdominal pain 12.5% (placebo 0.4%) nausea 12.5% (placebo 0.8%) oedema peripheral 12.5% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg headache 11.4% (placebo 6.4%) nasopharyngitis 9.8% (placebo 10.4%) abdominal pain 2.4% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg pyrexia 12.5% (placebo 0%) urinary tract infection 12.5% (placebo 1.6%) abdominal pain 0% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg nasopharyngitis 17.3% (placebo 10.4%) diarrhoea 7.1% (placebo 2.8%) headache 5.5% (placebo 6.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg pyrexia 20% (placebo 0%) abdominal pain 0% (placebo 0.4%) anaemia 0% (placebo 0.4%) NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4 mg headache 8.9% (placebo 2%) nasopharyngitis 8.1% (placebo 12.3%) blood creatine phosphokinase increased 5.7% (placebo 0.4%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2 mg nasopharyngitis 13% (placebo 12.3%) headache 7.3% (placebo 2%) herpes simplex 5.7% (placebo 0.8%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1 mg nasopharyngitis 10.5% (placebo 12.3%) headache 4.8% (placebo 2%) blood creatine phosphokinase increased 3.2% (placebo 0.4%) NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 High Dose abdominal pain 5% (placebo 2.5%) acne 5% (placebo 4.1%) headache 5% (placebo 8.2%) NCT03952559 · Phase 3 · registry result, not featured evidence Low Dose headache 5.8% (placebo 8.2%) bronchitis 5% (placebo 0.8%) covid-19 4.2% (placebo 2.5%) NCT03952559 · Phase 3 · registry result, not featured evidence Mid Dose headache 9.2% (placebo 8.2%) abdominal pain 4.2% (placebo 2.5%) covid-19 4.2% (placebo 2.5%) NCT03952559 · Phase 3 · registry result, not featured evidence High Dose nasopharyngitis 6.1% (placebo 4.9%) abdominal pain upper 3% (placebo 0.8%) chapped lips 3% (placebo 0%) NCT03952559 · Phase 3 · registry result, not featured evidence 4 mg covid-19 11% (placebo 2.2%) herpes zoster 9.8% (placebo 0%) nasopharyngitis 9.8% (placebo 5.4%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg covid-19 16.7% (placebo 2.2%) nasopharyngitis 13.1% (placebo 5.4%) blood creatine phosphokinase increased 6% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 16.4% (placebo 5.4%) upper respiratory tract infection 5.9% (placebo 4.3%) oral herpes 5.4% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg covid-19 13.3% (placebo 2.2%) nasopharyngitis 10.8% (placebo 5.4%) headache 5.6% (placebo 3.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg covid-19 15.2% (placebo 2.2%) nasopharyngitis 10.9% (placebo 5.4%) headache 5.4% (placebo 3.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 9.5% (placebo 5.4%) urinary tract infection 7.1% (placebo 1.1%) covid-19 4.8% (placebo 2.2%) NCT03334435 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 13.8% (placebo 5.4%) headache 6% (placebo 3.3%) upper respiratory tract infection 5.6% (placebo 4.3%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg covid-19 21.9% (placebo 2.2%) alanine aminotransferase increased 9.4% (placebo 0%) dermal cyst 6.3% (placebo 0%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg covid-19 9.9% (placebo 2.2%) vulvovaginal candidiasis 6.7% (placebo 0%) folliculitis 5.5% (placebo 0%) NCT03334435 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 20% (placebo 5.4%) pyrexia 4.4% (placebo 0%) blood creatine phosphokinase increased 2.2% (placebo 1.1%) NCT03334435 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 37% (placebo 10.3%) influenza 15.2% (placebo 3.4%) headache 10.9% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg covid-19 16.7% (placebo 13.8%) dysmenorrhoea 14.3% (placebo 0%) upper respiratory tract infection 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 57.1% (placebo 10.3%) covid-19 28.6% (placebo 13.8%) gastroenteritis 28.6% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence Placebo to 4 mg nasopharyngitis 50% (placebo 10.3%) abdominal pain upper 16.7% (placebo 0%) migraine 16.7% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg to 2 mg nasopharyngitis 18.8% (placebo 10.3%) upper respiratory tract infection 18.8% (placebo 3.4%) arthralgia 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 4 mg to 4 mg covid-19 25% (placebo 13.8%) bronchitis 18.8% (placebo 0%) herpes simplex 18.8% (placebo 6.9%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 19.6% (placebo 10.3%) influenza 8.2% (placebo 3.4%) headache 7.6% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 22.7% (placebo 10.3%) covid-19 18.2% (placebo 13.8%) herpes zoster 13.6% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 2 mg covid-19 14.8% (placebo 13.8%) vulvovaginal candidiasis 14.3% (placebo 0%) nasopharyngitis 11.1% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 4 mg covid-19 19.2% (placebo 13.8%) herpes zoster 15.4% (placebo 0%) skin infection 15.4% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence Placebo to 2 mg acne 9.1% (placebo 0%) anaemia 9.1% (placebo 0%) covid-19 9.1% (placebo 13.8%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 2 mg headache 20% (placebo 3.4%) vulvovaginal candidiasis 20% (placebo 0%) covid-19 16% (placebo 13.8%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg to 1 mg nasopharyngitis 33.3% (placebo 10.3%) covid-19 12.5% (placebo 13.8%) pain in extremity 12.5% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg nasopharyngitis 17.2% (placebo 10.3%) folliculitis 9.7% (placebo 0%) headache 8.6% (placebo 3.4%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg dysmenorrhoea 23.1% (placebo 0%) covid-19 17.6% (placebo 13.8%) nasopharyngitis 11.8% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg to 2 mg herpes simplex 15.4% (placebo 6.9%) herpes zoster 15.4% (placebo 0%) nasopharyngitis 15.4% (placebo 10.3%) NCT03428100 · Phase 3 · registry result, not featured evidence 1 mg to 4 mg conjunctivitis 21.4% (placebo 0%) covid-19 21.4% (placebo 13.8%) uterine polypectomy 16.7% (placebo 0%) NCT03428100 · Phase 3 · registry result, not featured evidence 2 mg upper respiratory tract infection 6.9% (placebo 6.2%) nasopharyngitis 6.2% (placebo 7.5%) diarrhoea 4.1% (placebo 1.4%) NCT03435081 · Phase 3 · registry result, not featured evidence 2 mg prostate cancer 9.1% (placebo 0%) upper respiratory tract infection 8.6% (placebo 6.2%) urinary tract infection 8.6% (placebo 2.1%) NCT03435081 · Phase 3 · registry result, not featured evidence 1 mg upper respiratory tract infection 6.1% (placebo 6.2%) back pain 2% (placebo 0.7%) blood creatine phosphokinase increased 2% (placebo 0.7%) NCT03435081 · Phase 3 · registry result, not featured evidence 1 mg upper respiratory tract infection 10.5% (placebo 6.2%) ovarian cyst ruptured 6.7% (placebo 0%) actinic keratosis 5.3% (placebo 0%) NCT03435081 · Phase 3 · registry result, not featured evidence 4 mg nasopharyngitis 15.3% (placebo 12%) folliculitis 5.4% (placebo 0%) upper respiratory tract infection 2.7% (placebo 1.9%) NCT03733301 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 11% (placebo 12%) upper respiratory tract infection 7.3% (placebo 1.9%) folliculitis 3.7% (placebo 0%) NCT03733301 · Phase 3 · registry result, not featured evidence 4 mg blood creatine phosphokinase increased 13.2% (placebo 2%) headache 13.2% (placebo 0%) nasopharyngitis 10.5% (placebo 4.1%) NCT02576938 · Phase 2 · registry result, not featured evidence 2 mg dermatitis atopic 8.1% (placebo 10.2%) gastrooesophageal reflux disease 5.4% (placebo 0%) headache 5.4% (placebo 0%) NCT02576938 · Phase 2 · registry result, not featured evidence | 15 mgg covid-19 23.1% (placebo 0%) acne 19.2% (placebo 3.3%) dermatitis atopic 19.2% (placebo 13.3%) NCT03607422 · Phase 3 show 38 more results15 mg covid-19 27.3% (placebo 0%) upper respiratory tract infection 21.8% (placebo 1.7%) acne 18.2% (placebo 3.3%) NCT03607422 · Phase 3 15 mg QD acne 10.3% (placebo 3.3%) upper respiratory tract infection 10.3% (placebo 1.7%) oropharyngeal pain 6.9% (placebo 0%) NCT03607422 · Phase 3 15 mg covid-19 31.7% (placebo 0%) acne 19.2% (placebo 3.3%) blood creatine phosphokinase increased 17.3% (placebo 1.7%) NCT03607422 · Phase 3 15 mg covid-19 31.9% (placebo 0%) dermatitis atopic 17.9% (placebo 13.3%) upper respiratory tract infection 14.4% (placebo 1.7%) NCT03607422 · Phase 3 15 mg QD acne 12.8% (placebo 3.3%) headache 7% (placebo 3.3%) nasopharyngitis 6.2% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 41.4% (placebo 0%) acne 34.5% (placebo 3.3%) dermatitis atopic 24.1% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 32.2% (placebo 0%) blood creatine phosphokinase increased 18.6% (placebo 1.7%) acne 11.9% (placebo 3.3%) NCT03607422 · Phase 3 30 mg QD acne 14.5% (placebo 3.3%) blood creatine phosphokinase increased 9.7% (placebo 1.7%) headache 8.1% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 39.4% (placebo 0%) acne 25% (placebo 3.3%) dermatitis atopic 15.4% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 29.8% (placebo 0%) blood creatine phosphokinase increased 18.3% (placebo 1.7%) dermatitis atopic 14.9% (placebo 13.3%) NCT03607422 · Phase 3 30 mg QD acne 15% (placebo 3.3%) nasopharyngitis 8.1% (placebo 3.3%) headache 6.5% (placebo 3.3%) NCT03607422 · Phase 3 15 mg covid-19 20% (placebo 0%) acne 16.7% (placebo 1.6%) blood creatine phosphokinase increased 16.7% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD covid-19 25% (placebo 0%) upper respiratory tract infection 21.9% (placebo 8.2%) blood creatine phosphokinase increased 12.5% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD acne 14.1% (placebo 1.6%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) headache 7.8% (placebo 3.3%) NCT03569293 · Phase 3 15 mg covid-19 38.2% (placebo 0%) dermatitis atopic 18.6% (placebo 3.3%) upper respiratory tract infection 18.6% (placebo 8.2%) NCT03569293 · Phase 3 15 mg covid-19 28.6% (placebo 0%) nasopharyngitis 16.5% (placebo 1.6%) dermatitis atopic 16% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD upper respiratory tract infection 9.6% (placebo 8.2%) nasopharyngitis 7.9% (placebo 1.6%) acne 5.4% (placebo 1.6%) NCT03569293 · Phase 3 30 mg acne 37% (placebo 1.6%) upper respiratory tract infection 33.3% (placebo 8.2%) dermatitis atopic 29.6% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD covid-19 35.9% (placebo 0%) acne 28.1% (placebo 1.6%) upper respiratory tract infection 28.1% (placebo 8.2%) NCT03569293 · Phase 3 30 mg QD acne 15.6% (placebo 1.6%) upper respiratory tract infection 12.5% (placebo 8.2%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 38.1% (placebo 0%) acne 22.9% (placebo 1.6%) blood creatine phosphokinase increased 17.1% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 35.1% (placebo 0%) acne 18.9% (placebo 1.6%) dermatitis atopic 18% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD acne 16.5% (placebo 1.6%) upper respiratory tract infection 12.8% (placebo 8.2%) nasopharyngitis 11.5% (placebo 1.6%) NCT03569293 · Phase 3 15 mg acne 7% nasopharyngitis 5.7% upper respiratory tract infection 3.5% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg nasopharyngitis 11.1% dermatitis atopic 8.3% upper respiratory tract infection 6.9% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg then 30 mg dermatitis atopic 16% nasopharyngitis 4.2% acne 2.8% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 13.8% nasopharyngitis 9.1% dermatitis atopic 3.9% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg then 15 mg dermatitis atopic 12% nasopharyngitis 7.5% acne 6% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg dermatitis atopic 16.5% acne 6.6% eczema 5.5% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 20.5% covid-19 13.4% blood creatine phosphokinase increased 13% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg acne 22.9% dermatitis atopic 19.1% blood creatine phosphokinase increased 14.8% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg QD acne 18.7% dermatitis atopic 10.5% blood creatine phosphokinase increased 7.6% NCT03738397 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) nasopharyngitis 11.9% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 11.9% (placebo 5.4%) nasopharyngitis 9.5% (placebo 1.1%) blood creatine phosphokinase increased 7.1% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 22.8% (placebo 5.4%) dermatitis atopic 19.3% (placebo 2.2%) acne 11.4% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg acne 14.3% (placebo 1.1%) upper respiratory tract infection 11.9% (placebo 5.4%) blood creatine phosphokinase increased 9.5% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 14.3% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eTrial phases differ: Phase 4 versus Phase 3.
- fPopulation comparability has not been reviewed for 42 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
baricitinib
show 5 more results
show 17 more results
show 15 more results
show 15 more results
show 15 more results
show 17 more results
show 10 more results
show 15 more results
show 6 more results
show 10 more results
show 12 more results
show 12 more results
+ 31 further endpoints in the CSV export.
upadacitinib
show 7 more results
show 38 more results
show 7 more results
show 8 more results
show 7 more results
show 7 more results
show 7 more results
show 13 more results
show 7 more results
show 3 more results
show 3 more results
show 3 more results
+ 16 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly and partners
NCT01710358 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.
Next expected readout: March 2027 · NCT04870203 (registry estimate)
Reported efficacy
Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12): ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) (met)
Result source: NCT02265705
upadacitinib · Rinvoq
Marketed by AbbVie
NCT02675426 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).
Next expected readout: March 2027 · NCT07636057 (registry estimate)
Reported efficacy
Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)
Result source: NCT03086343
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | baricitinib | upadacitinib |
|---|---|---|
| ACR20 | 61.7% vs 39.5%+22.2 vs placeboNCT0172105711 other results
| 63.8% vs 35.7%+28.1 vs placeboNCT0267542649 other results
|
| ACR50 | 44.1% vs 21.5%+22.6 vs placeboNCT0172105713 other results
| 52.1% vs 28.3%vs MethotrexateNCT0270687341 other results
|
| ACR70 | 24.2% vs 7.9%+16.3 vs placeboNCT0172105717 other results
| 20.8% vs 5.9%+14.9 vs placeboNCT0267542641 other results
|
| DAS28-CRP remission | —Trial running · NCT04870203 | 48.3% vs 18.5%vs MethotrexateNCT0270687322 other results
|
| HAQ-DI, change | -0.5 vs -0.3−0.2 vs placeboNCT0172105711 other results
| -0.6 vs -0.3−0.3 vs placeboNCT0267542632 other results
|
| Modified Sharp score, change | 0.3 vs 0.8−0.5 vs placeboNCT017103582 other results
| 0.1 vs 0.7vs MethotrexateNCT027068734 other results
|
ACR20
- baricitinib
- 61.7% vs 39.5%+22.2 vs placeboNCT01721057
11 other results
- 55.4% vs 27.3% NCT01721044
- 65.9% vs 39.5% NCT01721057
- 69.6% vs 40.2% NCT01710358
- 58.6% vs 28.3% NCT02265705
- 76.7% vs 61.9% NCT01711359
- 78.1% vs 61.9% NCT01711359
- 46.3% vs 27.3% NCT01721044
- 44.8% vs 27.3% NCT01721044
- 48.9% vs 27.3% NCT01721044
- 73% vs 55.7% NCT01711359
- 72.6% vs 55.7% NCT01711359
- upadacitinib
- 63.8% vs 35.7%+28.1 vs placeboNCT02675426
49 other results
- 64.6% vs 28.4% NCT02706847
- 71.6% vs 31.4% NCT02955212
- 66.2% vs 35.7% NCT02675426
- 56.4% vs 28.4% NCT02706847
- 83.7% vs 42.9% NCT02720523
- 80% vs 42.9% NCT02720523
- 75.5% vs 42.9% NCT02720523
- 67.7% vs 41.2% NCT02706951
- 75.7% vs 54.1% NCT02706873
- 71.2% vs 41.2% NCT02706951
- 77.1% vs 54.1% NCT02706873
- 22.2% vs 8.6% NCT02675426
- 27.4% vs 10.7% NCT02706847
- 25.4% vs 5.9% NCT02955212
- 28.3% vs 8.6% NCT02675426
- 24.8% vs 10.7% NCT02706847
- 24.5% vs 8.2% NCT02720523
- 34% vs 8.2% NCT02720523
- 30.6% vs 8.2% NCT02720523
- 78.9% vs 58.6% NCT02706873
- 78% vs 58.6% NCT02706873
- 85.2% vs 57.1% NCT02706873
- 78.6% vs 57.1% NCT02706873
- 85.5% vs 57.1% NCT02706873
- 81.6% vs 50% NCT02066389
- 76.6% vs 50% NCT02066389
- 70.9% vs 35.2% NCT01960855
- 81.6% vs 50% NCT02066389
- 72.7% vs 35.2% NCT01960855
- 73.5% vs 50% NCT02066389
- 63.5% vs 35.2% NCT01960855
- 64.6% vs 50% NCT02066389
- 55.6% vs 35.2% NCT01960855
- 41.5% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 29.3% vs 42.1% NCT03682705
- 24.4% vs 21.1% NCT03682705
- 30.8% vs 47.4% NCT03682705
- 30.8% vs 36.8% NCT03682705
- 23.1% vs 42.1% NCT03682705
- 12.8% vs 21.1% NCT03682705
- 64.5% vs 47.4% NCT03682705
- 64.5% vs 36.8% NCT03682705
- 51.6% vs 42.1% NCT03682705
- 45.2% vs 21.1% NCT03682705
- 34.1% vs 47.4% NCT03682705
- 39% vs 36.8% NCT03682705
- 22% vs 42.1% NCT03682705
- 14.6% vs 21.1% NCT03682705
ACR50
- baricitinib
- 44.1% vs 21.5%+22.6 vs placeboNCT01721057
13 other results
- 29.4% vs 13.1% NCT01721044
- 33.5% vs 12.7% NCT01721057
- 28.2% vs 8% NCT01721044
- 41.5% vs 21.5% NCT01721057
- 23% vs 13.1% NCT01721044
- 33.6% vs 12.7% NCT01721057
- 20.1% vs 8% NCT01721044
- 59.7% vs 43.3% NCT01711359
- 63.3% vs 43.3% NCT01711359
- 54.7% vs 32.9% NCT01711359
- 60% vs 32.9% NCT01711359
- 57.2% vs 37.6% NCT01711359
- 61.9% vs 37.6% NCT01711359
- upadacitinib
- 52.1% vs 28.3%vs MethotrexateNCT02706873
41 other results
- 56.4% vs 28.3% NCT02706873
- 38% vs 14.9% NCT02675426
- 34.1% vs 11.8% NCT02706847
- 40.8% vs 8.3% NCT02955212
- 43.4% vs 14.9% NCT02675426
- 35.8% vs 11.8% NCT02706847
- 65.3% vs 16.3% NCT02720523
- 58% vs 16.3% NCT02720523
- 40.8% vs 16.3% NCT02720523
- 60.3% vs 33.4% NCT02706873
- 41.9% vs 15.3% NCT02706951
- 65.6% vs 33.4% NCT02706873
- 52.1% vs 15.3% NCT02706951
- 66.7% vs 21.4% NCT02706873
- 71.4% vs 21.4% NCT02706873
- 60% vs 21.4% NCT02706873
- 29.3% vs 21.1% NCT03682705
- 19.5% vs 5.3% NCT03682705
- 17.1% vs 10.5% NCT03682705
- 4.9% vs 0% NCT03682705
- 43.8% vs 19.6% NCT02066389
- 12.8% vs 21.1% NCT03682705
- 12.8% vs 5.3% NCT03682705
- 2.6% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 44.7% vs 19.6% NCT02066389
- 40% vs 17% NCT01960855
- 45.2% vs 21.1% NCT03682705
- 41.9% vs 5.3% NCT03682705
- 19.4% vs 10.5% NCT03682705
- 16.1% vs 0% NCT03682705
- 50% vs 19.6% NCT02066389
- 43.6% vs 17% NCT01960855
- 49% vs 19.6% NCT02066389
- 38.5% vs 17% NCT01960855
- 17.1% vs 21.1% NCT03682705
- 7.3% vs 5.3% NCT03682705
- 4.9% vs 10.5% NCT03682705
- 0% vs 0% NCT03682705
- 39.6% vs 19.6% NCT02066389
- 24.1% vs 17% NCT01960855
ACR70
- baricitinib
- 24.2% vs 7.9%+16.3 vs placeboNCT01721057
17 other results
- 16.9% vs 3.4% NCT01721044
- 18.1% vs 3.1% NCT01721057
- 11.3% vs 2.3% NCT01721044
- 25.3% vs 7.9% NCT01721057
- 13.2% vs 3.4% NCT01721044
- 17.9% vs 3.1% NCT01721057
- 12.6% vs 2.3% NCT01721044
- 42.1% vs 21.4% NCT01711359
- 39.5% vs 21.4% NCT01711359
- 30.8% vs 15.7% NCT01711359
- 33.5% vs 15.7% NCT01711359
- 42.1% vs 25.2% NCT01711359
- 46% vs 25.2% NCT01711359
- 29% vs 0% NCT01469013
- 29% vs 0% NCT01469013
- 21% vs 0% NCT01469013
- 13% vs 0% NCT01469013
- upadacitinib
- 20.8% vs 5.9%+14.9 vs placeboNCT02675426
41 other results
- 11.6% vs 6.5% NCT02706847
- 21.3% vs 3.6% NCT02955212
- 26.5% vs 5.9% NCT02675426
- 23% vs 6.5% NCT02706847
- 34.7% vs 2% NCT02720523
- 28% vs 2% NCT02720523
- 20.4% vs 2% NCT02720523
- 44.5% vs 18.5% NCT02706873
- 22.6% vs 2.8% NCT02706951
- 32.5% vs 14% NCT02706873
- 49.7% vs 18.5% NCT02706873
- 33% vs 2.8% NCT02706951
- 36.9% vs 14% NCT02706873
- 51.9% vs 0% NCT02706873
- 64.3% vs 0% NCT02706873
- 34.5% vs 0% NCT02706873
- 14.6% vs 15.8% NCT03682705
- 4.9% vs 0% NCT03682705
- 4.9% vs 0% NCT03682705
- 2.4% vs 0% NCT03682705
- 25% vs 6.5% NCT02066389
- 5.1% vs 15.8% NCT03682705
- 2.6% vs 0% NCT03682705
- 2.6% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 27.7% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 25.8% vs 15.8% NCT03682705
- 17.7% vs 0% NCT03682705
- 9.7% vs 0% NCT03682705
- 8.1% vs 0% NCT03682705
- 16% vs 6.5% NCT02066389
- 21.8% vs 3.6% NCT01960855
- 30.6% vs 6.5% NCT02066389
- 26.9% vs 3.6% NCT01960855
- 9.8% vs 15.8% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 0% vs 0% NCT03682705
- 23.4% vs 6.5% NCT02066389
- 13% vs 3.6% NCT01960855
DAS28-CRP remission
- baricitinib
- —Trial running · NCT04870203
- upadacitinib
- 48.3% vs 18.5%vs MethotrexateNCT02706873
22 other results
- 50% vs 18.5% NCT02706873
- 30.8% vs 10% NCT02675426
- 29.6% vs 5.3% NCT02955212
- 28.3% vs 10% NCT02675426
- 57.1% vs 6.1% NCT02720523
- 50% vs 6.1% NCT02720523
- 36.7% vs 6.1% NCT02720523
- 28.1% vs 8.3% NCT02706951
- 30% vs 13.3% NCT03086343
- 40.5% vs 8.3% NCT02706951
- 70.4% vs 17.9% NCT02706873
- 82.1% vs 17.9% NCT02706873
- 67.3% vs 17.9% NCT02706873
- 19.5% vs 10.5% NCT03682705
- 22.4% vs 14.9% NCT02066389
- 7.7% vs 10.5% NCT03682705
- 42.9% vs 14.9% NCT02066389
- 32.3% vs 10.5% NCT03682705
- 34% vs 14.9% NCT02066389
- 38.8% vs 14.9% NCT02066389
- 9.8% vs 10.5% NCT03682705
- 36.7% vs 14.9% NCT02066389
HAQ-DI, change
- baricitinib
- -0.5 vs -0.3−0.2 vs placeboNCT01721057
11 other results
- -0.4 vs -0.2 NCT01721044
- -0.5 vs -0.3 NCT01721057
- -0.4 vs -0.2 NCT01721044
- -0.7 vs -0.3 NCT01710358
- -0.6 vs -0.3 NCT02265705
- -1.0 vs -0.7 NCT01711359
- -0.9 vs -0.7 NCT01711359
- -0.5 vs -0.1 NCT01469013
- -0.4 vs -0.1 NCT01469013
- -0.4 vs -0.1 NCT01469013
- -0.3 vs -0.1 NCT01469013
- upadacitinib
- -0.6 vs -0.3−0.3 vs placeboNCT02675426
32 other results
- -0.4 vs -0.2 NCT02706847
- -0.6 vs -0.2 NCT02955212
- -0.5 vs -0.3 NCT02675426
- -0.4 vs -0.2 NCT02706847
- -0.5 vs -0.1 NCT02720523
- -0.5 vs -0.1 NCT02720523
- -0.4 vs -0.1 NCT02720523
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.8 vs -0.5 NCT02706873
- -0.9 vs -0.6 NCT02706873
- -0.7 vs -0.3 NCT02706951
- -0.9 vs -0.5 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.9 vs -0.2 NCT02706873
- -0.8 vs -0.2 NCT02706873
- -0.3 vs -0.3 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.1 vs -0.4 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.5 vs -0.3 NCT03682705
- -0.5 vs -0.2 NCT03682705
- -0.4 vs -0.4 NCT03682705
- -0.3 vs -0.2 NCT03682705
- -0.2 vs -0.3 NCT03682705
- -0.1 vs -0.2 NCT03682705
- -0.2 vs -0.4 NCT03682705
- -0.2 vs -0.2 NCT03682705
Modified Sharp score, change
- baricitinib
- 0.3 vs 0.8−0.5 vs placeboNCT01710358
2 other results
- 0.4 vs 0.6 NCT01711359
- 0.3 vs 0.6 NCT01711359
- upadacitinib
- 0.1 vs 0.7vs MethotrexateNCT02706873
4 other results
- 0.1 vs 0.7 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.2 vs 2.6 NCT02706873
- 0.9 vs 2.6 NCT02706873
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. baricitinib: 11 of 11 rows · upadacitinib: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | baricitinib Rows use multiple source trials | upadacitinib Rows use multiple source trials |
|---|---|---|
| Boolean Remission responder rate · % of participants | 7.2% (n=487) vs 1% (n=488) placebo @ 12wka,b NCT01710358 · Phase 3 4 other source trials13.8% (n=159) vs 5.7% (n=210) Methotrexate @ 12wk NCT01711359 · Phase 3 14.4% (n=215) vs 5.7% (n=210) Methotrexate @ 12wk NCT01711359 · Phase 3 · combination 7% (n=229) vs 0.4% (n=228) placebo @ 12wk2 mg NCT01721057 · Phase 3 6.6% (n=227) vs 0.4% (n=228) placebo @ 12wk4 mg NCT01721057 · Phase 3 | 9.8% (n=41) vs 0% (n=19) placebo @ 12wk60 mgc,a,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses2.6% (n=39) vs 0% (n=19) placebo @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 11.3% (n=62) vs 0% (n=19) placebo @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4% (n=41) vs 0% (n=19) placebo @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| CDAI absolute change · score | -23 vs -13.53 placebo score @ 12wka,b NCT01710358 · Phase 3 | -17.5 vs -14.57 placebo score @ 12wk60 mgc,a,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-16.7 vs -14.57 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -27 vs -14.57 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.51 vs -14.57 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| DAS28-CRP absolute change · score | -2.74 vs -2.01 Methotrexate score @ 24wkc,b NCT01711359 · Phase 3 show 1 more dose-2.82 vs -2.01 Methotrexate score @ 24wk NCT01711359 · Phase 3 · combination | -3.07 vs -2.15 Methotrexate score @ 24wk15 mgc,b NCT02706873 · Phase 3 show 1 more dose-3.34 vs -2.15 Methotrexate score @ 24wk30 mg NCT02706873 · Phase 3 |
| DAS28-ESR absolute change · score | -1.97 vs -1.16 placebo score @ 12wk4 mgc,a,b NCT01721057 · Phase 3 show 1 more dose-1.89 vs -1.16 placebo score @ 12wk2 mg NCT01721057 · Phase 3 | -1.41 vs -1.18 placebo score @ 12wk60 mgc,a,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-1.24 vs -1.18 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -2.53 vs -1.18 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -1.44 vs -1.18 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| FACIT-Fatigue absolute change · score | 9.6 vs 6.8 placebo score @ 12wkb,d NCT01710358 · Phase 3 4 other source trials8.7 vs 7.6 placebo score @ 12wk2 mg NCT01721057 · Phase 3 8.8 vs 7.6 placebo score @ 12wk4 mg NCT01721057 · Phase 3 8.8 vs 5.9 placebo score @ 12wk2 mg NCT01721044 · Phase 3 8.5 vs 5.9 placebo score @ 12wk4 mg NCT01721044 · Phase 3 | 7.91 vs 2.96 placebo score @ 12wk15 mgc,b,d NCT02675426 · Phase 3 show 1 more dose7.74 vs 2.96 placebo score @ 12wk30 mg NCT02675426 · Phase 3 |
| Morning Stiffness Duration absolute change · minutes | -55 vs -40 Methotrexate minutes @ 52wkc,b,e NCT01711359 · Phase 3 show 1 more dose-60 vs -40 Methotrexate minutes @ 52wk NCT01711359 · Phase 3 · combination | -94.56 vs -53.03 Methotrexate minutes @ 14wk15 mgc,b,e NCT02706951 · Phase 3 show 1 more dose-102.34 vs -53.03 Methotrexate minutes @ 14wk30 mg NCT02706951 · Phase 3 |
| SDAI absolute change · score | -18.17 vs -4.54 placebo score @ 12wk4 mgc,b NCT01469013 · Phase 2 show 3 more doses-16.85 vs -4.54 placebo score @ 12wk2 mg NCT01469013 · Phase 2 -18.02 vs -4.54 placebo score @ 12wk8 mg NCT01469013 · Phase 2 -13.11 vs -4.54 placebo score @ 12wk1 mg NCT01469013 · Phase 2 | -18.01 vs -14.44 placebo score @ 12wk60 mgc,b NCT03682705 · Phase 2 · registry result, not featured evidence show 3 more doses-17.12 vs -14.44 placebo score @ 12wk20 mg NCT03682705 · Phase 2 · registry result, not featured evidence -28.06 vs -14.44 placebo score @ 12wk15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination -16.73 vs -14.44 placebo score @ 12wk5 mg NCT03682705 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 5.9%Baricitinibf NCT01710358 · Phase 3 show 43 more results—Baricitinib Follow-up NCT01710358 · Phase 3 —Baricitinib Treatment A NCT01710358 · Phase 3 —BaricitinibTreatment B NCT01710358 · Phase 3 15%Baricitinib NCT01711359 · Phase 3 19.5%Baricitinib + MTX NCT01711359 · Phase 3 · combination —Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination —Baricitinib - Follow-up NCT01711359 · Phase 3 6.2%4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 —4 mg NCT01469013 · Phase 2 —2 mg NCT01469013 · Phase 2 —8 mg NCT01469013 · Phase 2 —1 mg NCT01469013 · Phase 2 —4 mg NCT01721057 · Phase 3 10.1%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 8.3%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 10.7%4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 9.8%2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 51.7%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 51.1%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 55.7%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 60.8%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 33.7%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 94.1%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 75.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 70.2%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 95.8%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 100%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 76.9%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 72.8%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | —15 mgf NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.6%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 8.2%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 12.6%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 14%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 7.3%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 7.4%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 4.7%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 4.8%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 9.7%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 4.1%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 12%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 7.3%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 12.8%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 6.5%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 14.6%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 10%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 14%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 6%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 12%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 9.1%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 16.4%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 7.3%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.7%Baricitinibf NCT01710358 · Phase 3 show 43 more results—Baricitinib Follow-up NCT01710358 · Phase 3 —Baricitinib Treatment A NCT01710358 · Phase 3 —BaricitinibTreatment B NCT01710358 · Phase 3 6.3%Baricitinib NCT01711359 · Phase 3 11.2%Baricitinib + MTX NCT01711359 · Phase 3 · combination —Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination —Baricitinib - Follow-up NCT01711359 · Phase 3 1.4%4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —4 mg NCT02265705 · Phase 3 —Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 —4 mg NCT01469013 · Phase 2 —2 mg NCT01469013 · Phase 2 —8 mg NCT01469013 · Phase 2 —1 mg NCT01469013 · Phase 2 —4 mg NCT01721057 · Phase 3 5.3%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 4.4%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 5.6%4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 —4 mg NCT01721044 · Phase 3 4%2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 13.5%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 12.6%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 8.3%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 5.7%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 6%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 12.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 21.8%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 18.1%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 11.5%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 10.9%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 14.5%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 16.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | —15 mgf NCT02675426 · Phase 3 show 55 more results—15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 1.4%15 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 4.1%30 mg NCT02675426 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy 5.7%15 mg NCT02706873 · Phase 3 —15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 · monotherapy 3.5%30 mg NCT02706873 · Phase 3 —30 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 · monotherapy 5.5%7.5 mg NCT02706873 · Phase 3 —7.5 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 · monotherapy —15 mg QD NCT03086343 · Phase 3 —15 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 —30 mg QD NCT03086343 · Phase 3 2.3%15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 —15 mg NCT02706951 · Phase 3 1.4%30 mg NCT02706951 · Phase 3 —30 mg NCT02706951 · Phase 3 0.6%15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 —15 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02955212 · Phase 3 · registry result, not featured evidence —15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 0%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence —12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence —6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 2.4%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 1.6%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 2.4%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 2%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 10%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 3.6%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 10.9%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —Baricitinibf NCT01710358 · Phase 3 show 43 more results0%Baricitinib Follow-up NCT01710358 · Phase 3 5.3%Baricitinib Treatment A NCT01710358 · Phase 3 3.8%BaricitinibTreatment B NCT01710358 · Phase 3 7.5%Baricitinib NCT01711359 · Phase 3 7.9%Baricitinib + MTX NCT01711359 · Phase 3 · combination 0%Baricitinib + MTX - Follow-up NCT01711359 · Phase 3 · combination 0%Baricitinib - Follow-up NCT01711359 · Phase 3 2.8%4 mg NCT02265705 · Phase 3 1.7%4 mg NCT02265705 · Phase 3 2.5%4 mg NCT02265705 · Phase 3 9.5%Placebo to Baricitinib Treatment P NCT02265705 · Phase 3 0%4 mg NCT01469013 · Phase 2 4.2%2 mg NCT01469013 · Phase 2 4.2%8 mg NCT01469013 · Phase 2 0%1 mg NCT01469013 · Phase 2 5.3%4 mg NCT01721057 · Phase 3 —4 mg NCT01721057 · Phase 3 4.5%4 mg NCT01721057 · Phase 3 2.6%2 mg NCT01721057 · Phase 3 —2 mg NCT01721057 · Phase 3 0%2 mg NCT01721057 · Phase 3 —4 mg NCT01721044 · Phase 3 0%4 mg NCT01721044 · Phase 3 10.7%4 mg NCT01721044 · Phase 3 —2 mg NCT01721044 · Phase 3 11.1%2 mg NCT01721044 · Phase 3 4.6%2 mg NCT01721044 · Phase 3 31.3%4 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 29.5%2 mg NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 23.7%4 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 22.9%2 mg NCT04086745 · Phase 4 · registry result, not featured evidence · pooled 20%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 30%4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence —4 mg NCT01885078 · Phase 3 · registry result, not featured evidence 37.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence 27.7%2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence —2 mg NCT01885078 · Phase 3 · registry result, not featured evidence | 28.1%15 mgf NCT02675426 · Phase 3 show 55 more results4.5%15 mg NCT02675426 · Phase 3 10.6%15 mg NCT02675426 · Phase 3 —15 mg NCT02675426 · Phase 3 3.2%30 mg NCT02675426 · Phase 3 31.8%30 mg NCT02675426 · Phase 3 —30 mg NCT02675426 · Phase 3 15.5%15 mg NCT02706873 · Phase 3 · monotherapy —15 mg NCT02706873 · Phase 3 5%15 mg NCT02706873 · Phase 3 · monotherapy 21.5%15 mg NCT02706873 · Phase 3 · monotherapy —30 mg NCT02706873 · Phase 3 6.4%30 mg NCT02706873 · Phase 3 · monotherapy 22.6%30 mg NCT02706873 · Phase 3 · monotherapy —7.5 mg NCT02706873 · Phase 3 9.1%7.5 mg NCT02706873 · Phase 3 · monotherapy 23.6%7.5 mg NCT02706873 · Phase 3 · monotherapy 4%15 mg QD NCT03086343 · Phase 3 23.6%15 mg QD NCT03086343 · Phase 3 19%30 mg QD NCT03086343 · Phase 3 35.3%30 mg QD NCT03086343 · Phase 3 5.1%15 mg NCT02706951 · Phase 3 10.7%15 mg NCT02706951 · Phase 3 29.9%15 mg NCT02706951 · Phase 3 2.8%30 mg NCT02706951 · Phase 3 24.1%30 mg NCT02706951 · Phase 3 —15 mg NCT02706847 · Phase 3 15.2%15 mg NCT02706847 · Phase 3 5.5%15 mg NCT02706847 · Phase 3 36.9%15 mg NCT02706847 · Phase 3 —30 mg NCT02706847 · Phase 3 7.3%30 mg NCT02706847 · Phase 3 29.6%30 mg NCT02706847 · Phase 3 17.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 7.1%15 mg NCT02955212 · Phase 3 · registry result, not featured evidence 21.9%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%15 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 27.3%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 10%30 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 13.8%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 2%7.5 mg NCT02720523 · Phase 2/3 · registry result, not featured evidence 22.5%12 mg BID/30 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 13.8%6 mg BID/15 mg QD NCT02049138 · Phase 2 · registry result, not featured evidence 0%60 mg NCT03682705 · Phase 2 · registry result, not featured evidence 5.1%20 mg NCT03682705 · Phase 2 · registry result, not featured evidence 0%15 mg/60 mg NCT03682705 · Phase 2 · registry result, not featured evidence · combination 7.3%5 mg NCT03682705 · Phase 2 · registry result, not featured evidence 4.1%24 mg QD NCT02066389 · Phase 2 · registry result, not featured evidence 6%18 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 2%12 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 4%6 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 0%3 mg BID NCT02066389 · Phase 2 · registry result, not featured evidence 1.8%18 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 0%12 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%6 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence 3.6%3 mg BID NCT01960855 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | f alanine aminotransferase increased 0% (placebo 0%) anaemia 0% (placebo 0%) back pain 0% (placebo 0%) NCT01710358 · Phase 3 show 30 more resultsnasopharyngitis 7.6% (placebo 6.1%) urinary tract infection 4.3% (placebo 0%) bronchitis 3.9% (placebo 0%) NCT01710358 · Phase 3 nasopharyngitis 5.7% (placebo 6.1%) upper respiratory tract infection 3.1% (placebo 0%) bronchitis 2.8% (placebo 0%) NCT01710358 · Phase 3 nasopharyngitis 10.1% upper respiratory tract infection 7.5% gastroenteritis 6.3% NCT01711359 · Phase 3 nasopharyngitis 9.8% nausea 9.3% upper respiratory tract infection 7.4% NCT01711359 · Phase 3 · combination abdominal discomfort 0% abdominal pain upper 0% alanine aminotransferase increased 0% NCT01711359 · Phase 3 · combination 4 mg upper respiratory tract infection 19.3% (placebo 0%) hyperlipidaemia 11% (placebo 0%) urinary tract infection 9% (placebo 0%) NCT02265705 · Phase 3 4 mg arthralgia 5.2% (placebo 0%) abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) NCT02265705 · Phase 3 4 mg upper respiratory tract infection 9.2% (placebo 0%) hyperlipidaemia 7.5% (placebo 0%) benign prostatic hyperplasia 7.1% (placebo 0%) NCT02265705 · Phase 3 blood creatine phosphokinase increased 6.8% (placebo 0%) upper respiratory tract infection 6.8% (placebo 0%) nasopharyngitis 5.4% (placebo 0%) NCT02265705 · Phase 3 4 mg blood creatine phosphokinase increased 8.3% (placebo 4.1%) liver function test abnormal 8.3% (placebo 0%) nasopharyngitis 8.3% (placebo 12.2%) NCT01469013 · Phase 2 2 mg hepatic function abnormal 12.5% (placebo 0%) nasopharyngitis 8.3% (placebo 12.2%) cystitis 4.2% (placebo 4.1%) NCT01469013 · Phase 2 8 mg blood creatine phosphokinase increased 12.5% (placebo 4.1%) hepatic function abnormal 12.5% (placebo 0%) hypercholesterolaemia 12.5% (placebo 0%) NCT01469013 · Phase 2 1 mg nasopharyngitis 8.3% (placebo 12.2%) anaemia 4.2% (placebo 0%) chronic sinusitis 4.2% (placebo 0%) NCT01469013 · Phase 2 4 mg upper respiratory tract infection 10.6% (placebo 0%) nasopharyngitis 7.9% (placebo 0%) blood creatine phosphokinase increased 6.6% (placebo 5.9%) NCT01721057 · Phase 3 4 mg cough 4.5% (placebo 0%) dyspnoea 4.5% (placebo 0%) gastritis 4.5% (placebo 0%) NCT01721057 · Phase 3 2 mg headache 6.6% (placebo 0%) upper respiratory tract infection 6.1% (placebo 0%) urinary tract infection 5.2% (placebo 0%) NCT01721057 · Phase 3 2 mg abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) acne 0% (placebo 0%) NCT01721057 · Phase 3 4 mg cervicitis 5.6% (placebo 0%) abdominal pain 0% (placebo 0%) abdominal pain upper 0% (placebo 0%) NCT01721044 · Phase 3 4 mg headache 6.8% (placebo 0%) bronchitis 5.6% (placebo 0%) nausea 5.6% (placebo 0%) NCT01721044 · Phase 3 2 mg cellulitis 11.1% (placebo 0%) insomnia 11.1% (placebo 0%) lymphopenia 11.1% (placebo 0%) NCT01721044 · Phase 3 2 mg headache 9.8% (placebo 0%) upper respiratory tract infection 8.6% (placebo 0%) nasopharyngitis 6.9% (placebo 5.3%) NCT01721044 · Phase 3 4 mg covid-19 23.3% nasopharyngitis 13.8% urinary tract infection 11.4% NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 2 mg covid-19 20.8% nasopharyngitis 11.6% urinary tract infection 11.3% NCT03915964 · Phase 4 · registry result, not featured evidence · pooled 4 mg bronchitis 11.3% nasopharyngitis 11.3% upper respiratory tract infection 10.9% NCT01885078 · Phase 3 · registry result, not featured evidence 4 mg bronchitis 10.9% nasopharyngitis 9.8% influenza 9.4% NCT01885078 · Phase 3 · registry result, not featured evidence 2 mg upper respiratory tract infection 19.5% urinary tract infection 17.8% bronchitis 16.2% NCT01885078 · Phase 3 · registry result, not featured evidence 2 mg nasopharyngitis 9.1% upper respiratory tract infection 7.8% bronchitis 7.4% NCT01885078 · Phase 3 · registry result, not featured evidence | 15 mgf upper respiratory tract infection 19.8% (placebo 4.1%) nasopharyngitis 18.5% (placebo 4.1%) urinary tract infection 17% (placebo 3.6%) NCT02675426 · Phase 3 show 48 more results15 mg nausea 6.8% (placebo 3.2%) nasopharyngitis 5.4% (placebo 4.1%) upper respiratory tract infection 5.4% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 8.9% (placebo 0%) rheumatoid arthritis 4.5% (placebo 4.5%) fall 2.8% (placebo 0.5%) NCT02675426 · Phase 3 30 mg nasopharyngitis 5.9% (placebo 4.1%) upper respiratory tract infection 5.5% (placebo 4.1%) headache 3.7% (placebo 5.4%) NCT02675426 · Phase 3 30 mg upper respiratory tract infection 17.8% (placebo 4.1%) urinary tract infection 14.3% (placebo 3.6%) nasopharyngitis 14% (placebo 4.1%) NCT02675426 · Phase 3 15 mg covid-19 10.5% rheumatoid arthritis 9.4% urinary tract infection 7.2% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 6.3% nasopharyngitis 5.7% nausea 5.7% NCT02706873 · Phase 3 · monotherapy 15 mg upper respiratory tract infection 15.5% nasopharyngitis 15.1% urinary tract infection 13.6% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 10.8% upper respiratory tract infection 7.3% urinary tract infection 5.7% NCT02706873 · Phase 3 · monotherapy 30 mg blood creatine phosphokinase increased 16.2% nasopharyngitis 16.2% hypertension 14% NCT02706873 · Phase 3 · monotherapy 15 mg QD upper respiratory tract infection 8.6% nasopharyngitis 7.3% urinary tract infection 6.6% NCT03086343 · Phase 3 30 mg QD hypertension 23.5% upper respiratory tract infection 23.5% bronchitis 17.6% NCT03086343 · Phase 3 15 mg urinary tract infection 4.6% upper respiratory tract infection 4.1% blood creatine phosphokinase increased 2.3% NCT02706951 · Phase 3 15 mg nasopharyngitis 17.6% rheumatoid arthritis 14.2% urinary tract infection 13.5% NCT02706951 · Phase 3 30 mg urinary tract infection 4.7% blood creatine phosphokinase increased 4.2% upper respiratory tract infection 2.8% NCT02706951 · Phase 3 30 mg blood creatine phosphokinase increased 18.6% urinary tract infection 15.1% upper respiratory tract infection 14.8% NCT02706951 · Phase 3 15 mg rheumatoid arthritis 9.4% (placebo 5.9%) urinary tract infection 8% (placebo 5.9%) back pain 5.8% (placebo 2.4%) NCT02706847 · Phase 3 15 mg urinary tract infection 9.8% (placebo 5.9%) upper respiratory tract infection 7.9% (placebo 7.7%) bronchitis 4.3% (placebo 2.4%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 31.4% (placebo 7.7%) urinary tract infection 18.2% (placebo 5.9%) nasopharyngitis 14.4% (placebo 6.5%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 6.7% (placebo 7.7%) nasopharyngitis 5.5% (placebo 6.5%) urinary tract infection 5.5% (placebo 5.9%) NCT02706847 · Phase 3 30 mg upper respiratory tract infection 27.9% (placebo 7.7%) urinary tract infection 20.4% (placebo 5.9%) nasopharyngitis 17.1% (placebo 6.5%) NCT02706847 · Phase 3 15 mg upper respiratory tract infection 20.2% (placebo 6.5%) alanine aminotransferase increased 9.3% (placebo 1.2%) blood creatine phosphokinase increased 9% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 9.5% (placebo 6.5%) alanine aminotransferase increased 5.3% (placebo 1.2%) anaemia 0% (placebo 0%) NCT02955212 · Phase 3 · registry result, not featured evidence 15 mg nasopharyngitis 54.7% (placebo 10.2%) herpes zoster 14.1% (placebo 2%) influenza 14.1% (placebo 4.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 15 mg nasopharyngitis 12.2% (placebo 10.2%) liver function test increased 6.1% (placebo 0%) constipation 4.1% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 43.9% (placebo 10.2%) constipation 15.2% (placebo 0%) herpes zoster 15.2% (placebo 2%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 30 mg nasopharyngitis 18% (placebo 10.2%) blood creatine phosphokinase increased 6% (placebo 0%) headache 6% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 53.8% (placebo 10.2%) stomatitis 20% (placebo 6.1%) hypertension 12.3% (placebo 0%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 7.5 mg nasopharyngitis 10.2% (placebo 10.2%) hypertension 6.1% (placebo 0%) stomatitis 6.1% (placebo 6.1%) NCT02720523 · Phase 2/3 · registry result, not featured evidence 12 mg BID/30 mg QD upper respiratory tract infection 20.3% urinary tract infection 15% herpes zoster 11.2% NCT02049138 · Phase 2 · registry result, not featured evidence 6 mg BID/15 mg QD upper respiratory tract infection 9.9% nasopharyngitis 9.5% urinary tract infection 9.5% NCT02049138 · Phase 2 · registry result, not featured evidence 60 mg urinary tract infection 9.8% (placebo 0%) diarrhoea 7.3% (placebo 0%) rheumatoid arthritis 7.3% (placebo 10.5%) NCT03682705 · Phase 2 · registry result, not featured evidence 20 mg rheumatoid arthritis 7.7% (placebo 10.5%) upper respiratory tract infection 7.7% (placebo 5.3%) alopecia 5.1% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 15 mg/60 mg upper respiratory tract infection 6.5% (placebo 5.3%) arthralgia 1.6% (placebo 5.3%) cough 1.6% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence · combination 5 mg rheumatoid arthritis 7.3% (placebo 10.5%) upper respiratory tract infection 4.9% (placebo 5.3%) urinary tract infection 4.9% (placebo 0%) NCT03682705 · Phase 2 · registry result, not featured evidence 24 mg QD nasopharyngitis 6.1% (placebo 2%) back pain 2% (placebo 0%) blood creatine phosphokinase increased 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID blood creatine phosphokinase increased 4% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 12 mg BID influenza 8% (placebo 0%) nasopharyngitis 8% (placebo 2%) blood creatine phosphokinase increased 6% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 6 mg BID back pain 6% (placebo 0%) nasopharyngitis 4% (placebo 2%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 3 mg BID headache 4% (placebo 2%) back pain 2% (placebo 0%) cough 2% (placebo 0%) NCT02066389 · Phase 2 · registry result, not featured evidence 18 mg BID urinary tract infection 12.7% (placebo 3.6%) blood creatine phosphokinase increased 9.1% (placebo 0%) constipation 7.3% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 12 mg BID upper respiratory tract infection 7.3% (placebo 1.8%) headache 5.5% (placebo 1.8%) leukopenia 5.5% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 6 mg BID headache 5.5% (placebo 1.8%) hyperlipidaemia 3.6% (placebo 1.8%) constipation 1.8% (placebo 0%) NCT01960855 · Phase 2 · registry result, not featured evidence 3 mg BID nausea 7.3% (placebo 1.8%) arthralgia 5.5% (placebo 0%) headache 5.5% (placebo 1.8%) NCT01960855 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 14 weeks versus 52 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
baricitinib
show 13 more results
+ 73 further endpoints in the CSV export.
upadacitinib
show 21 more results
show 16 more results
show 22 more results
show 23 more results
show 4 more results
show 2 more results
show 18 more results
show 3 more results
show 20 more results
show 15 more results
show 15 more results
show 15 more results
+ 6 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · upadacitinib's landscape